Cell viability and PSA secretion assays in LNCaP cells: A tiered in vitro approach to screen chemicals with a prostate-mediated effect on male reproduction within the ReProTect project

Reproductive Toxicology

Volumn 30, Issue 1, 2010, Pages 25-35

  Lorenzetti, Stefano ^a   Marcoccia, Daniele ^a   Narciso, Laura ^a   Mantovani, Alberto ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Androgen receptor; Biomarker; Cytotoxicity; Endocrine disrupter; Feasibility; Male fertility; Test battery; Testing strategy

Indexed keywords

2 HYDROXYFLUTAMIDE; 4,4' ISOPROPYLIDENEDIPHENOL; ACETOACETIC ACID DERIVATIVE; ACETOACETIC ACID METHYL ESTER; ANDROSTANOLONE; ANTIANDROGEN; CADMIUM CHLORIDE HEMIPENTAHYDRATE; CARBENDAZIM; DIMETHYL SULFOXIDE; LINURON; METHYLTESTOSTERONE; METHYOXYACETIC ACID; NITROBENZENE; NITROFEN; PHOSPHINOTHRICIN; PHTHALIC ACID DIBUTYL ESTER; PROSTATE SPECIFIC ANTIGEN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VINCLOZOLIN; ANDROGEN;

ARTICLE; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MALE FERTILITY; MALE GENITAL SYSTEM; REPRODUCTIVE TOXICITY; SCREENING TEST; TOXICITY TESTING; ANIMAL TESTING ALTERNATIVE; BIOASSAY; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; PATHOLOGY; PROCEDURES; PROSTATE; REPRODUCIBILITY; REPRODUCTION; SECRETION (PROCESS); STANDARDS; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMAL TESTING ALTERNATIVES; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; REPRODUCIBILITY OF RESULTS; REPRODUCTION;

EID: 77954087867     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2010.03.008     Document Type: Article

References (54)

1. Anonymous. The Fourth EC report on the statistics on the number of animals used for experimental and other scientific purposes in the Member States of the European Union. COM/2005/7 final. ; 2005. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2005:0007:FIN:EN:PDF.
2. Hareng L., Pellizzer C., Bremer S., Schwarz M., Hartung T. The integrated project ReProTect: a novel approach in reproductive toxicity hazard assessment. Reprod Toxicol 2005, 20:441-452.
3. Woodruff T.J., Carlson A., Schwartz J.M., Giudice L.C. Proceedings of the summit on environmental challenges to reproductive health and fertility: executive summary. Fertil Steril 2008, 89:e1-e20.
4. Bremer S., Balduzzi D., Cortvrindt R., Daston G., Eletti B., Galli A., et al. The effects of chemicals on mammalian fertility. The report and recommendations of ECVAM Workshop 53-the first strategic workshop of the EU ReProTect Project. Altern Lab Anim 2005, 33:391-416.
5. Mantovani A., Maranghi F. Risk assessment of chemicals potentially affecting male fertility. Contraception 2005, 72:308-313.
6. O'Shaughnessy P.J., Morris I.D., Huhtaniemi I., Baker P.J., Abel M.H. Role of androgen and gonadotrophins in the development and function of the Sertoli cells and Leydig cells: data from mutant and genetically modified mice. Mol Cell Endocrinol 2009, 306:2-8.
7. Jonsson M., Lundwall A., Malm J. The semenogelins: proteins with functions beyond reproduction?. Cell Mol Life Sci 2006, 63:2886-2888.
8. Veveris-Lowe T.L., Kruger S.J., Walsh T., Gardiner R.A., Clements J.A. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches. Semin Thromb Hemost 2007, 33:87-99.
9. Clements J.A., Willemsen N.M., Myers S.A., Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004, 41:265-312.
10. Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate-specific antigen. J Clin Oncol 2003, 21:383-391.
11. Pampalakis G., Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007, 1776:22-31.
12. McPhaul M.J. Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 2008, 22:373-388.
13. Finne P., Finne R., Auvinen A., Juusela H., Aro J., Määttänen L., et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000, 56:418-422.
14. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43:1809-1818.
15. Fizazi K., Navone N.M. Preclinical models of prostate cancer. Bull Cancer 2005, 92:129-141.
16. Anonymous. Guidance document on using in vitro data to estimate in vivo starting doses for acute toxicity. ; 2001. http://iccvam.niehs.nih.gov/docs/acutetox_docs/guidance0801/iv_guide.pdf.
17. Arnould R., Dubois J., Abikhalil F., Libert A., Ghanem G., Atassi G., et al. Comparison of two cytotoxicity assays-tetrazolium derivative reduction (MTT) and tritiated thymidine uptake on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res 1990, 10:145-154.
18. Eriksson S., Vehniainen M., Jansen T., Meretoja V., Saviranta P., Pettersson K., et al. Dual-label time-resolved immunofluorometric assay of free and total prostate-specific antigen based on recombinant Fab fragments. Clin Chem 2000, 46:658-666.
19. Kim J., Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004, 93:233-241.
20. Mylchreest E., Foster P.M. DBP exerts its antiandrogenic activity by indirectly interfering with androgen signaling pathways. Toxicol Appl Pharmacol 2000, 168:174-175.
21. Luu-The V., Bélanger A., Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008, 22:207-221.
22. Sunami O., Kunimatsu T., Yamada T., Yabushita S., Sukata T., Miyata K., et al. Evaluation of a 5-day Hershberger assay using young mature male rats: methyltestosterone and p,p′-DDE, but not fenitrothion, exhibited androgenic or antiandrogenic activity in vivo. J Toxicol Sci 2000, 25:403-415.
23. Kelly W.K., Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993, 149:607-609.
24. Gray L.E., Ostby J., Furr J., Wolf C.J., Lambright C., Parks L., et al. Effects of environmental antiandrogens on reproductive development in experimental animals. Hum Reprod Update 2001, 7:248-264.
25. Reissigl A., Klocker H., Pointner J., Ennemoser O., Falk M., Bartsch G. Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels. Prostate 1997, 30:243-247.
26. Finne P., Auvinen A., Määttänen L., Tammela T.L., Ruutu M., Juusela H., et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0μg per liter. Eur Urol 2008, 54:362-370.
27. Wetherill Y.B., Fisher N.L., Staubach A., Danielsen M., de Vere White R.W., Knudsen K.E. Xenosestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res 2005, 65:54-65.
28. Arnold J.T., Liu X., Allen J.D., Le H., McFann K.K., Blackman M.R. Androgen receptor or estrogen receptor-b blockade alters DHEA-, DHT-, and E2-induced proliferation and PSA production in human prostate cancer cells. Prostate 2007, 67:1152-1162.
29. Ishioka J., Hara S., Isaacs J.T., Tomura A., Nishikawa K., Kageyama Y. Suppression of mutant androgen receptors by flutamide. Int J Urol 2009, 16:516-521.
30. Lee H.J., Chattopadhyay S., Gong E.Y., Ahn R.S., Lee K. Antiandrogenic effects of bisphenol A and nonylphenol on the function of androgen receptor. Toxicol Sci 2003, 75:40-46.
31. Xu L.C., Sun H., Chen J.F., Bian Q., Qian J., Song L., et al. Evaluation of androgen receptor transcriptional activities of bisphenol A, octylphenol and nonylphenol in vitro. Toxicology 2005, 216:197-203.
32. Sun H., Xu L.C., Chen J.F., Song L., Wang X.R. Effect of bisphenol A, tetrachlorobisphenol A and pentachlorophenol on the transcriptional activities of androgen receptor-mediated reporter gene. Food Chem Toxicol 2006, 44:1916-1921.
33. Wetherill Y.B., Petre C.E., Monk K.R., Puga A., Knudsen K.E. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther 2002, 1:515-524.
34. Hess-Wilson J.K., Webb S.L., Daly H.K., Leung Y.K., Boldison J., Comstock C.E., et al. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect 2007, 115:1646-1653.
35. Schulte-Hermann R., Wogan G.N., Berry C., Brown N.A., Czeizel A., Giavini E., et al. Analysis of reproductive toxicity and classification of glufosinate-ammonium. Regul Toxicol Pharmacol 2006, 44:S1-S76.
36. Bremner W.J., Millar M.R., Sharpe R.M., Saunders P.T. Immunohistochemical localization of androgen receptors in the rat testis: evidence for stage-dependent expression and regulation by androgens. Endocrinology 1994, 135:1227-1234.
37. Tirado O.M., Martinez E.D., Rodriguez O.C., Danielsen M., Selva D.M., Reventós J., et al. Methoxyacetic acid disregulation of androgen receptor and androgen-binding protein expression in adult rat testis. Biol Reprod 2003, 68:1437-1446.
38. Bagchi G., Hurst C.H., Waxman D.J. Interactions of methoxyacetic acid with androgen receptor. Toxicol Appl Pharmacol 2009, 238:101-110.
39. O'Hara G.P., Chan P.K., Harris J.C., Burke S.S., Smith J.M., Hayes A.W. The effect of nitrofen [4-(2,4-dichlorophenoxy)nitrobenzene] on the reproductive performance of male rats. Toxicology 1983, 28:323-333.
40. Tomura A., Goto K., Morinaga H., Nomura M., Okabe T., Yanase T., et al. The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. J Biol Chem 2001, 276:28395-28401.
41. Gleave M.E., Hsieh J.T., Wu H.C., von Eschenbach A.C., Chung L.W. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992, 52:1598-1605.
42. Arnold J.T., Liu X., Allen J.D., Le H., McFann K.K., Blackman M.R. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 2007, 67:1152-1162.
43. Shin J.H., Moon H.J., Kang I.H., Kim T.S., Lee S.J., Ahn J.Y., et al. OECD validation of the rodent Hershberger assay using three reference chemicals; 17alpha-methyltestosterone, procymidone, and p,p′-DDE. Arch Toxicol 2007, 81:309-318.
44. Kang I.H., Kim H.S., Shin J.H., Kim T.S., Moon H.J., Kim I.Y., et al. Comparison of anti-androgenic activity of flutamide, vinclozolin, procymidone, linuron, and p,p′-DDE in rodent 10-day Hershberger assay. Toxicology 2004, 199:145-159.
45. Gray L.E., Wolf C., Lambright C., Mann P., Price M., Cooper R.L., et al. Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p′-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicol Ind Health 1999, 15:94-118.
46. Lambright C., Ostby J., Bobseine K., Wilson V., Hotchkiss A.K., Mann P.C., et al. Cellular and molecular mechanisms of action of linuron: an antiandrogenic herbicide that produces reproductive malformations in male rats. Toxicol Sci 2000, 56:389-399.
47. Lee B.M., Koo H.J. Hershberger assay for antiandrogenic effects of phthalates. J Toxicol Environ Health A 2007, 70:1365-1370.
48. Arriazu R., Pozuelo J.M., Martín R., Rodríguez R., Santamaría L. Quantitative and immunohistochemical evaluation of PCNA, androgen receptors, apoptosis, and Glutathione-S-Transferase P1 on preneoplastic changes induced by cadmium and zinc chloride in the rat ventral prostate. Prostate 2005, 63:347-357.
49. 2+. Biol Chem. 1985, 260:8683-8689.
50. Parrish A.R., Sallam K., Nyman D.W., Orozco J., Cress A.E., Dalkin B.L., et al. Culturing precision-cut human prostate slices as an in vitro model of prostate pathobiology. Cell Biol Toxicol 2002, 18:205-219.
51. Yamada T., Sumida K., Saito K., Ueda S., Yabushita S., Sukata T., et al. Functional genomics may allow accurate categorization of the benzimidazole fungicide benomyl: lack of ability to act via steroid-receptor-mediated mechanisms. Toxicol Appl Pharmacol 2005, 205:11-30.
52. Okubo T., Yokoyama Y., Kano K., Soya Y., Kano I. Estimation of estrogenic and antiestrogenic activities of selected pesticides by MCF-7 cell proliferation assay. Arch Environ Contam Toxicol 2004, 46:445-453.
53. Yamasaki K., Sawaki M., Ohta R., Okuda H., Katayama S., Yamada T., et al. OECD validation of the Hershberger assay in Japan: phase 2 dose response of methyltestosterone, vinclozolin, and p,p′-DDE. Environ Health Perspect 2003, 111:1912-1919.
54. Prins G.S., Tang W.Y., Belmonte J., Ho S.M. Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol 2008, 102:134-138.